Walleye Capital
PCVX icon

Walleye Capital’s Vaxcyte PCVX Stock Holding History

Walleye Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Buy
+2,000
New +$109K ﹤0.01% 3816
2025
Q1 		– Sell
-800
Closed -$65.5K – 4915
2024
Q4 		$65.5K Hold
800
– – ﹤0.01% 4287
2024
Q3 		$91.4K Buy
+800
New +$72.1K ﹤0.01% 4427
2024
Q2 		– Sell
-1,400
Closed -$95.6K – 5899
2024
Q1 		$95.6K Buy
1,400
+600
+75% +$41.5K ﹤0.01% 4415
2023
Q4 		$50.2K Buy
+800
New +$41.5K ﹤0.01% 4300
2023
Q3 		– Sell
-1,300
Closed -$64.9K – 5206
2023
Q2 		$64.9K Hold
1,300
– – ﹤0.01% 3572
2023
Q1 		$48.7K Sell
1,300
-1,300
-50% -$55.1K ﹤0.01% 3212
2022
Q4 		$125K Buy
+2,600
New +$102K ﹤0.01% 2283

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Walleye Capital's PCVX Position: Q2 2026 in Review

Walleye Capital reduced its Vaxcyte (PCVX) stake by 96% in Q2 2026, selling an estimated $2.65M and leaving 1,942 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #3836.

Walleye Capital first reported a position in PCVX in Q1 2022 and has held it in 15 quarters since. The position peaked at $12.1M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Walleye Capital held 1,942 shares of Vaxcyte worth $113K as of Q2 2026.
  • Walleye Capital sold 48,708 Vaxcyte shares in Q2 2026, an estimated $2.65M.
  • Vaxcyte made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3836 holding.
  • Walleye Capital first reported a position in Vaxcyte in Q1 2022 and has held it in 15 quarters since.
  • Walleye Capital's Vaxcyte position peaked at $12.1M in Q4 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.